AZD8359 / AstraZeneca - LARVOL DELTA

CRIUS-1: First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

AZD8359: A novel CD8‑biased T cell engager designed to deliver a wider therapeutic window in prostate cancer (AACR 2026) - "These results collectively support the concept that CD8-biased, low-affinity TCR engagement of the tumor-restricted antigen STEAP2 by AZD8359 confers a wider preclinical therapeutic index compared to conventional TCEs in prostate cancer. This preclinical package underpins the clinical evaluation of AZD8359 planned in 2026."

Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4 • CD8 • STEAP1 • STEAP2

CRIUS-1: First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer (clinicaltrials.gov) - P1/2 | N=42 | Not yet recruiting | Sponsor: AstraZeneca

First-in-human • New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor